BioSpace News Archive

Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Bausch Health Companies Inc. (“Bausch Health”) (NYSE/TSX: BHC), and its partner Norgine B.V. (“Norgine”) today announced the U.S. launch and availability of PLENVU

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the publication of new patient-reported outcomes (PRO) data demonstrating that adding ERLEADA® (apalutamide) to androgen-deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high-risk for development of metastases

Aquestive Therapeutics Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that Lori J. Braender, Esq. will join the company as Senior Vice President, General Counsel effective as of September 10.

eGlobalTech has partnered with the Neuroendocrine Tumor Research Foundation (NETRF) to host the DC Walk for Carcinoid Cancer. Both organizations are raising money to fund neuroendocrine tumor research for cures and more effective treatments

Imagine being able to treat diabetes without needles. For more than 114 million Chinese patients, it can be a reality. New research studies indicate needle-free injection is a viable therapy for diabetes and effective blood glucose control.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and fiscal 2018 earnings results at 7 a.m. Eastern time Thursday, October 11, 2018 followed by a one-hour conference call with Walgreens Boots Alliance management beginning at 8:30 a.m. Eastern time.

Blue Earth Diagnostics, a molecular imaging diagnostics company, announced the peer-reviewed publication of results from an investigational clinical trial (“LOCATE”) evaluating the impact of 18F fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer after initial prostate cancer treatment and negative or equivocal findings on standard-of-care imaging.

ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund

Tilray Inc. (NASDAQ:TLRY), a global leader in cannabis research, production and distribution, announced today that Tilray 2:100, a product produced at Tilray’s federally licensed, Good Manufacturing Practice (GMP)-certified facility in Canada, was successfully imported into the United Kingdom, to supply a pediatric patient in need.

CynergisTek (NYSE AMERICAN: CTEK), a leader in healthcare cybersecurity and information assurance, today announced it began providing its new Biomedical Device Security Risk Assessment service to multiple health systems, including a large, 28-hospital health system.